Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Fineline Cube Mar 27, 2026
Company Deals

GSK Partners with SPH Keyuan Trade to Relaunch Engerix B – Hepatitis B Vaccine Targets China’s Adult Self-Paid Market

Fineline Cube Mar 26, 2026
Company Deals

MSD to Acquire Terns Pharmaceuticals for $6.7 Billion – TERN-701 BCR::ABL1 Inhibitor Targets Chronic Myeloid Leukemia

Fineline Cube Mar 26, 2026
Company Deals

Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification

Fineline Cube Mar 26, 2026
Company Deals

Thermo Fisher Partners with SHL Medical – Autoinjector Manufacturing Expansion Targets U.S. Drug-Device Combination Market

Fineline Cube Mar 26, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa

Fineline Cube Mar 28, 2026
Company Drug

Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11

Fineline Cube Mar 28, 2026
Company Drug

Jiangsu Simcere and AnDiConBio’s Anti-Influenza Drug ADC189 Doses First Patient in Phase III Study

Fineline Cube Aug 29, 2024

JIANGSU—In a significant development for the pharmaceutical industry, Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096),...

Company Drug

Sino Biopharmaceutical’s Anlotinib-Penpulimab Combo Meets Milestone in Phase III HCC Study

Fineline Cube Aug 29, 2024

HONG KONG—Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced...

Company Deals

Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development

Fineline Cube Aug 29, 2024

CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100...

Company Medical Device

Advancing Peripheral Artery Disease Care: Boston Scientific’s JETSTREAM Receives Marketing Nod in China

Fineline Cube Aug 29, 2024

NEW YORK—Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical solutions, has secured a...

Policy / Regulatory

China’s New Medical Device Regulations: A Comprehensive Framework for Industry Growth and Safety

Fineline Cube Aug 29, 2024

BEIJING—China’s National Medical Products Administration (NMPA) has unveiled a draft proposal for the “Medical Device...

Company

Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs

Fineline Cube Aug 29, 2024

Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong...

Company Deals

Tigermed Partners with Beijing Government to Open North Headquarters, Expanding Collaboration in Biotech

Fineline Cube Aug 29, 2024

Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347)...

Company

Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues

Fineline Cube Aug 29, 2024

Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported...

Company

Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report

Fineline Cube Aug 29, 2024

Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176),...

Company

Online Pharmacy Service Drives Jianke.com’s Revenue Growth in H1 2024 Amid Diverse Business Segments

Fineline Cube Aug 29, 2024

Jianke.com, a China-based smart healthcare service platform, has unveiled its financial report for the first...

Company Drug

Jiangxi Jemincare Secures First Generic Approval for GSK’s Requip in China

Fineline Cube Aug 28, 2024

Jiangxi Jemincare Group, based in China, has received marketing approval from the National Medical Products...

Company

AstraZeneca to Invest $135 Million in Swedish Biomanufacturing Facility Expansion

Fineline Cube Aug 28, 2024

AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based biopharmaceutical leader, has announced a plan to...

Company Deals

Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China

Fineline Cube Aug 28, 2024

Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing...

Company Drug

Sanofi Halts Flu Vaccine Distribution in China Amid Potency Concerns

Fineline Cube Aug 28, 2024

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has reportedly suspended the distribution and sale of...

Company Deals

Frontier Biotechnologies to Sell 70% of API Unit to Duo Rui Pharma for RMB 10 Million

Fineline Cube Aug 28, 2024

Nanjing-based Frontier Biotechnologies Inc. is poised to divest a 70% stake in its peptide active...

Company

Johnson & Johnson China’s Cardiovascular and Professional Solutions Division Head, Kevin Chen, Resigns for New Opportunities

Fineline Cube Aug 28, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading US multinational conglomerate, has announced the resignation...

Company

Everest Medicines Reports 158% Revenue Growth in 2024 H1, Driven by Pharmaceutical Sales and Operational Efficiency

Fineline Cube Aug 28, 2024

Everest Medicines, a China-based biopharmaceutical company listed on the Hong Kong Stock Exchange (HKG: 1952),...

Company Drug

JW Therapeutics’ CAR-T Therapy Carteyva Secures NMPA Approval for Mantle Cell Lymphoma Indication

Fineline Cube Aug 28, 2024

JW Therapeutics, a biopharmaceutical company based in China and listed on the Hong Kong Stock...

Company Drug

Shanghai-Based ANEXT Commences Clinical Trials for Exosome Product ANEXT FIT CELL in Respiratory Conditions

Fineline Cube Aug 28, 2024

ANEXT, a Shanghai-based exosome specialist, has launched two clinical studies for their product ANEXT FIT...

Company

Shanghai Fosun Pharmaceutical Reports 5.31% YOY Revenue Growth and Strong R&D Investment in 2024H1 Report

Fineline Cube Aug 28, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd, listed on the Shanghai Stock Exchange (SHA: 600196) and...

Posts pagination

1 … 282 283 284 … 642

Recent updates

  • UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa
  • Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11
  • FDA Approves Rocket Pharma’s Kresladi – First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I
  • C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market
  • Novo Nordisk’s Awiqli Wins FDA Approval – World’s First Once-Weekly Basal Insulin for Type 2 Diabetes
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

UCB’s Bimzelx Wins NMPA Approval for Two New Indications – IL-17A/F Dual-Target Antibody Expands into Psoriasis and Hidradenitis Suppurativa

Company Drug

Enhertu Wins China Approval for HER2+ Early Breast Cancer – ADC Sequential Therapy Shows 67% pCR Rate in Phase III DESTINY-Breast11

Company Drug

FDA Approves Rocket Pharma’s Kresladi – First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I

Company Deals

C-Ray Therapeutics Partners with SHINE Technologies – Lu-177 Supply Agreement Targets China Radiopharmaceutical Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.